Skip to main content

Advertisement

SpringerLink
Log in

Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer’s Disease-Diabetes Dual Therapy

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

At the present time, treatment of two most common degenerative disorders of elderly population i.e., Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s disease (AD) is a major concern worldwide. As there are several evidences that proved strong linkages between these two disorders, the idea of using dual therapeutic agent for both the diseases might be considered as a good initiative. Earlier reports have revealed that oral anti-diabetic drugs such as peroxisome proliferator activated receptor γ (PPARγ) agonists (thiazolidinediones) when used in T2DM patients suffering from AD showed improved memory and cognition. However, the underlying mechanism still needs to be deciphered. Therefore, the present study was carried out to find whether glimepiride, an oral antidiabetic drug which is a PPARγ agonist could inhibit the activity of acetylcholine esterase (AChE) enzyme. Actually, AChE inhibitors seize the breakdown of acetylcholine which forms the main therapeutic strategy for AD. Here, glimepiride showed dose dependent inhibitory activity against AChE enzyme with IC50 value of 235 μM. Kinetic analysis showed competitive inhibition, which was verified by in silico docking studies. Glimepiride was found to interact with AChE enzyme at the same locus as that of substrate acetylcholine iodide (AChI). Interestingly, amino acid residues, Q71, Y72, V73, D74, W86, N87, Y124, S125, W286, F295, F297, Y337, F338 and Y341 of AChE were found to be common for ‘glimepiride–AChE interaction’ as well as ‘AChI–AChE interaction’. Thus the present computational and kinetics study concludes that glimepiride and other thiazolidinediones derivatives could form the basis of future dual therapy against diabetes associated neurological disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cummings JL (2004) Alzheimer’s disease. N Engl J Med 351:56–67

    Article  CAS  PubMed  Google Scholar 

  2. Forstl H, Kurz A (1999) Clinical features of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 249:288–290

    Article  CAS  PubMed  Google Scholar 

  3. Melnikova I (2007) Therapies for Alzheimer’s disease. Nat Rev Drug Discov 6:341–352

    Article  CAS  PubMed  Google Scholar 

  4. Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9:387–398

    Article  CAS  PubMed  Google Scholar 

  5. Hitzeman N (2006) Cholinesterase inhibitors for Alzheimer’s disease. Am Fam Physician 74:747–759

    PubMed  Google Scholar 

  6. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881–891

    Article  CAS  PubMed  Google Scholar 

  7. Sabbagh MN (2009) Drug development for Alzheimer’s disease: where are we now and where are we headed. Am J Geriatr Pharmacother 7:167–185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease, The Tacrine Collaborative Study Group. N Engl J Med 327:1253–1259

    Article  CAS  PubMed  Google Scholar 

  9. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS (1995) Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacol Sin 16:391–395

    CAS  Google Scholar 

  10. AD 2000 Collaborative Group (2000) Long-term donepezil treatmentin 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 363:2105–2115

    Google Scholar 

  11. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I (1991) Atomic structure of Acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253:872–879

    Article  CAS  PubMed  Google Scholar 

  12. Ferris SH (2003) Evaluation of memantine for the treatment of Alzheimer’s disease. Expert Opin Pharmacother 4:2305–2313

    Article  CAS  PubMed  Google Scholar 

  13. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347–372

    Article  CAS  PubMed  Google Scholar 

  14. León R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev 33:139–189

    Article  PubMed  Google Scholar 

  15. Lin L (2008) Commonality between diabetes and Alzheimer’s disease and a new strategy for the therapy. Clin Med Pathol 1:83–91

    PubMed  PubMed Central  Google Scholar 

  16. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment. Br J Clin Pharmacol 71:365–376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Park S (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer’s disease evidence from animal models. J Clin Neurol 7:10–18

    Article  PubMed  PubMed Central  Google Scholar 

  18. Priyadarshini M, Kamal MA, Greig NH, Realef M, Abuzenadah AM, Chaudhary AG, Damanhouri GA (2012) Alzheimer’s disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets 11:482–489

    Article  CAS  PubMed  Google Scholar 

  19. Exalto L, Whitmer R, Kappele L, Biessels G (2012) An update on type 2 diabetes, vascular dementia and Alzheimer’s disease. Exp Gerontol 47:858–864

    Article  CAS  PubMed  Google Scholar 

  20. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson E (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71:1057–1064

    Article  CAS  PubMed  Google Scholar 

  21. Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: a lifespan perspective. Lancet Neurol 7:184–190

    Article  PubMed  Google Scholar 

  22. Messier C, Gagnon M (2009) Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Diabetologia 52:2471–2474

    Article  CAS  PubMed  Google Scholar 

  23. Haan MN (2006) Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nat Clin Pract Neurol 2:159–166

    Article  CAS  PubMed  Google Scholar 

  24. Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 27:190–198

    Article  CAS  PubMed  Google Scholar 

  25. Rizvi SMD, Shakil S, Biswas D, Shakil S, Shaikh S, Bagga P, Kamal MA (2014) Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease-diabetes type 2 linkage via an Enzoinformatics Study. CNS Neurol Disord Drug Targets 13:447–451

    Article  CAS  PubMed  Google Scholar 

  26. Shaikh S, Rizvi SMD, Shakil S, Riyaz S, Biswas D, Jahan R (2014) Forxiga (Dapagliflozin): plausible role in the treatment of diabetes associated neurological disorders. Biotechnol Appl Biochem. doi:10.1002/bab.1319

    PubMed  Google Scholar 

  27. Ingkaninan K, Temkitthawon P, Chuenchon K, Yuyaem T, Thongnoi W (2003) Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. J Ethnopharmacol 89:261–264

    Article  PubMed  Google Scholar 

  28. Liu F, Wang Y, Yan M, Zhang L, Pang T, Liao H (2013) Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons. Neurosci Lett 17:90–94

    Article  Google Scholar 

  29. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of b-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARg agonists. J Neurosci 20:558–567

    CAS  PubMed  Google Scholar 

  30. Heneka MT, Reyes-Irisarri E, Hull M, Kummer MP (2011) Impact and therapeutic potential of PPARs in Alzheimer’s disease. Curr Neuropharmacol 9:643–650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mushtaq G, Khan JA, Kumosani TA, Kamal MA (2015) Alzheimer’s disease and type 2 diabetes viachronic inflammatory mechanisms. Saudi J Biol Sci 22:4–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yarchoan M, Arnold SE (2014) Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63:2253–2261

    Article  PubMed  PubMed Central  Google Scholar 

  33. Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH (2014) Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol Ser A Biol Sci Med Sci 69:1299–1305

    Article  Google Scholar 

  34. Gupta R, Gupta LK (2012) Improvement in long term and visuospatial memory following chronic pioglitazone in mouse model of Alzheimer’s disease. Pharmacol Biochem Behav 102:184–190

    Article  CAS  PubMed  Google Scholar 

  35. Houghton PJ, Agbedahunsi JM, Adegbulugbe A (2004) Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 65:2893–2896

    Article  CAS  PubMed  Google Scholar 

  36. Gutiérrez M, Arévaloa B, Martínezb G, Valdésa F, Vallejosc G, Carmonad U, Martine AS (2015) Synthesis, molecular docking and design of Tetra hydroquinolines as acetylcholinesterase inhibitors. J Chem Pharm Res 7:351–358

    Google Scholar 

  37. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950–958

    PubMed  Google Scholar 

  38. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2009) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626–1633

    Article  PubMed  Google Scholar 

  39. Shaikh S, Ahmad SS, Ansari MA, Shakil S, Rizvi SMD, Shakil S, Tabrez S, Akhtar S, Kamal MA (2014) Prediction of comparative inhibition efficiency for a novel natural ligand, Galangin against human brain Acetylcholinesterase, butyrylcholinesterase and 5-Lipoxygenase: a Neuroinformatics study. CNS Neurol Disord Drug Targets 13:452–459

    Article  CAS  PubMed  Google Scholar 

  40. Somani G, Kulkarni C, Shinde P, Shelke R, Laddha K, Sathaye S (2015) In vitro acetylcholinesterase inhibition by psoralen using molecular docking and enzymatic studies. J Pharm Bioallied Sci 7:32–36

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Geromichalos GD, Lamari FN, Papandreou MA, Trafalis DT, Margarity M, Papageorgiou A, Sinakodx ZJ (2012) Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. Agric Food Chem 60:6131–6138

    Article  CAS  Google Scholar 

  42. Shaikh S, Zainab T, Shakil S, Rizvi SMD (2015) A neuroinformatics study to compare inhibition efficiency of three natural ligands (Fawcettimine, Cernuine and Lycodine) against Human Brain Acetylcholinesterase. Network Comput Neural Syst 26:26–35

    Google Scholar 

  43. Alam A, Shaikh S, Ahmad SS, Ansari MA, Shakil S, Rizvi SMD, Shakil S, Imran M, Haneef M, Abuzenadah AM, Kamal MA (2014) Molecular interaction of human brain acetylcholinesterase with a natural inhibitor Huperzine-B. An Enzoinformatics approach. CNS Neurol Disord Drug Targets 13:487–490

    Article  CAS  PubMed  Google Scholar 

  44. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) Beta amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 65:407–416

    Article  CAS  PubMed  Google Scholar 

  45. Xu Y, Colletier JP, Weik M, Jiang H, Moult J, Silman I, Sussman JL (2008) Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys J 95:2500–2511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Shaikh S is supported by INSPIRE grant from Department of Science & Technology, New Delhi, India (Grant Number: IF130056), which is sincerely acknowledged. Shazi Shakil thanks all of the staff of Center of Innovation in Personalized Medicine (CIPM), King Abdulaziz University, Saudi Arabia for continued support.

Author information

Authors and Affiliations

  1. Department of Biosciences, Integral University, Lucknow, 226026, India

    Syed Mohd. Danish Rizvi & Sibhghatulla Shaikh

  2. Department of Bioengineering, Integral University, Lucknow, 226026, India

    Deeba Naaz, Adnan Ahmad & Mohd. Haneef

  3. KACST Technology Innovation Center for Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

    Shazi Shakil & Adel M. Abuzenadah

  4. Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia

    Shazi Shakil & Adel M. Abuzenadah

Authors
  1. Syed Mohd. Danish Rizvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sibhghatulla Shaikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deeba Naaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shazi Shakil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adnan Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohd. Haneef
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Adel M. Abuzenadah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shazi Shakil.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rizvi, S.M.D., Shaikh, S., Naaz, D. et al. Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer’s Disease-Diabetes Dual Therapy. Neurochem Res 41, 1475–1482 (2016). https://doi.org/10.1007/s11064-016-1859-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-016-1859-3

Keywords

Search

Navigation